ADIT 2019 Abstracts

We will accept abstracts related to any topic of T1DM and T2DM management:

  • Pharmacological management of T1 and T2 DM

  • Non pharmacological management 

  • Lifestyle modification

  • Technologies 

  • Complications & Comorbidities 

  • Issues and dilemmas in clinical practice

Abstract submission checklist

  • It is mandatory to submit the abstract using online submission system (

  • The submission system will close on September 15, 2019.

  • Single author can submit two abstracts.

  • We will accept abstracts related to any topic of diabetes management.

  • Submitting author must disclose source of funding and his/hers potential COI.

  • It is sole responsibility of submitting author to obtain consent from all the participating authors.

  • Conference organizer assumes that submitting author contributed to the study in significant way.

  • Submitting author must register for the conference in seven days following acceptance notification. Failing to do so will result in automatic rejection of the abstract.

  • Submitting authors of accepted abstracts are entitled to early bird registration level until October 7, 2019.

  • The reviewers reserve the right to reject any abstract which does not meet the conference criteria.

  • All submitting authors will be notified of the outcome of their submission by October 1, 2019.

  • By submitting the abstract the authors consent to their abstract being reviewed and published in conference material and web page, where appropriate.

  • ADIT organizer reserves the right to edit an abstract for the conference program to meet formatting, space requirements and readability.

  • By submitting the abstract the author confirms accuracy of information and compliance with terms and conditions available on the web page: www.

noun_Best Content_1072021_00ccff.png

Paper has not been submitted to previous ADIT conferences


Submitting author participated and contributed to study in significant way

noun_Magnifying glass executive_1172384_

Disclosure of source of funding and potential COI